Glossary

Home > Education Resource Hub > Myeloma Glossary

Absolute neutrophil count (ANC)
Accelerated Approval
Actionable target
Active immunotherapy
Active multiple myeloma
Adaptive immunity
Adhesion molecules
Adjuvant
Adriamycin (doxorubicin)
Adverse event (AE)
Albumin
Alkeran®
Allogeneic stem cell transplant
Allograft
Aloxi® (palonosetron)
Alpha interferon
Amyloid protein
Amyloidosis
Anemia
Angiogenesis
Anthracycline
Antibody
Antibody-drug conjugate (ADC)
Antiemetic
Antigen
Antimicrobial
Anzemet® (dolasetron)
Apheresis
Apoptosis
Asthenia
Autograft
Autoimmune diseases
Autologous
Autologous stem cell transplant (ASCT)
Autologous transplant
B cell
B-cell maturation antigen (BCMA)
B lymphocyte
Balloon kyphoplasty
Basic fibroblast growth factor (bFGF)
Bcl-2
Bence-Jones protein
Beta 2-microglobulin (ß2-microglobulin or ß2-M)
Biaxin (clarithromycin)
Bispecific antibody
Bisphosphonate
Blood urea nitrogen (BUN)
Bone marrow
Bone marrow aspiration
Bone marrow biopsy
Bone remodeling
Bone resorption
Bone (skeletal) survey
C-reactive protein (CRP)
Calcium
Cancer vaccine
Catheter
CD34+
Checkpoint inhibitor
Chemistry profile
Chemobrain
Chemotherapy
Chimeric antigen receptor T (CAR T) cell therapy
Chromosomal abnormality
Chromosomal deletion
Chromosomal translocation
Chromosome
Chromosome analysis (cytogenetic testing)
Clinical trial
Colony-stimulating factor (CSF)
Complete blood count (CBC)
Complete remission
Complete response (CR)
Computed tomography (CT)
Computerized axial tomography (CAT)
Conditioning regimen
Consolidation Therapy
Conventional chemotherapy
Cord blood transplant
Corticosteroid
Coumadin® (also known as warfarin)
CR
Creatinine
Cryoglobulinemia
Cryopreservation
Cure
Cutaneous T-cell lymphoma (CTCL)
Cyclooxygenase-2 (COX-2)
Cyclophosphamide
Cyclosporine
Cytogenetic testing
Cytokine
Cytoxan®
Decadron® (dexamethasone)
Deep vein thrombosis (DVT)
Demographic
Dendritic cell
Dexamethasone
Dialysis
Disease-free survival
DMSO
DNA (deoxyribonucleic acid)
Donor Lymphocyte Infusion (DLI)
Doxil® (doxorubicin HCl liposome injection)
Electrolytes
Electrophoresis (EP)
Emend® (aprepitant)
Emerging therapy
End point
Endothelial cell
Engraftment
Enteritis
Erythropoiesis
Erythropoietin
Esophagitis
Event-free survival (EFS)
Expanded access
Extramedullary disease
Farydak® (Panobinostat)
Fast Track designation
Febrile neutropenia
Fibroblast growth factor 2 (FGF-2)
Filgrastim
Fluorescence in situ hybridization (FISH)
Fluoroscope
Formulation
Free light chain (FLC)
Frontline therapy
Grade 1 Adverse Event (AE)
Grade 2 AE
Grade 3 AE
Grade 4 AE
Graft-versus-host disease (GVHD)
Graft-versus-myeloma effect
Granulocyte
Granulocyte colony-stimulating factor (G-CSF)
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Growth factors
Hand-foot syndrome (HFS)
Heavily pre-treated
Heavy chain
Hematocrit
Hematologic
Hematopoiesis
Hematopoietic stem cells
Hemoglobin
Heparanase
Heparin
Hepatic impairment
High-dose chemotherapy
High risk myeloma
Hypercalcemia
Hypercalcemia of malignancy (HCM)
Hyperviscosity syndrome
Hypothyroidism
Immune response
Immune system
Immunoelectrophoresis
Immunofixation electrophoresis (IFE)
Immunoglobulin
Immunomodulatory agent
Immunomodulatory drugs or IMiDs®
Immunosuppressive drug
Immunotherapy
Induction therapy
Infusion Reaction
Institutional Review Board (IRB)
Interferon (IFN)
Interleukin 1 beta (IL-1b)
Interleukin 10 (IL-10)
Interleukin 12 (IL-12)
Interleukin 2 (IL-2)
Interleukin 4 (IL-4)
Interleukin 5 (IL-5)
Interleukin 6 (IL-6)
Interleukin 8 (IL-8)
Karyotyping
Kepivance® (palifermin)
Keratopathy
Kyphoplasty
Kyprolis™
Kytril® (granisetron)
Lactate dehydrogenase (LDH)
Leukine® (sargramostim)
Light chain
Liposome
Longitudinal study
Lymphocyte
Lymphoma
Magnetic resonance imaging (MRI)
Maintenance therapy
Malignant
Marketing Authorization Application (MAA)
Matrix metalloproteinases (MMPs)
Melphalan
Metastasis
Microvascular density (MVD)
Mini-allogeneic transplant
Mini-transplant
Minimal residual disease (MRD)
Minimal response
Mobilization
Monoclonal antibody
Monoclonal gammopathy of undetermined significance (MGUS)
Monoclonal (M) protein
Monocyte/Macrophage
Morphology
MP
Mucositis
Mycophenolate mofetil (CellCept®)
Myeloablation
Myelodysplastic syndrome (MDS)
Natural killer (NK) cell
Near complete response (near CR)
Nephrotoxicity
Neuropathic Pain
Neuropathy
Neutropenia
Neutrophil
New Drug Application (NDA)
Newly diagnosed disease
Non-myeloablative allogenic transplant
Nonsecretory myeloma
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Novel erythrocyte stimulating protein (NESP)
Nuclear factor ?B (NF-?B)
Office for Human Research Protections (OHRP)
Orphan Drug
Osteoblast
Osteoclast
Osteoclast-activating factor (OAF)
Osteolytic lesion
Osteonecrosis
Osteopenia
Osteoporosis
Overall response rate (ORR)
Overall survival (OS)
Paget’s Disease
Palifermin
Palliative
Palmar-plantar erythrodysesthesia (PPE)
Pamidronate (Aredia®)
Paraprotein
Parathyroid hormone-related peptide (PTHrP)
Partial response (PR)
PCROWD study
Performance status
Peripheral blood
Peripheral blood stem cell (PBSC)
Peripheral blood stem cell (PBSC) transplant
Peripheral edema
Peripheral neuropathy
Personalized medicine
Phase 1/2 study
Phase 1 study
Phase 2 study
Phase 3 study
Phase 4 study
Placebo
Plasma cell
Plasmablast
Plasmablastic morphology
Plasmacytoma
Plasmapheresis
Plateau phase
Platelets
Pomalyst (pomalidomide)
Positron emission tomography (PET)
Precision medicine
Preclinical studies
Precursor cell
Prednisone
Priority Review
Prognosis
Prognostic indicator
Progression-free survival (PFS)
Progressive disease
PROMISE study
Prophylactic
Proteasome inhibitors
Protocol
Pulmonary embolism
Pyrexia
Radiation therapy (or radiotherapy)
Radiopharmaceutical
Randomization
RANK L (also known as RANK Ligand)
Red blood cell (RBC)
Refractory disease
Relapsed disease
Renal Impairment
Response Rate or Overall Response
Revised International Staging System (R-ISS)
Revlimid® (lenalidomide)
RNA (ribonucleic acid)
Salvage therapy
Serum protein electrophoresis (SPEP)
Smoldering multiple myeloma (SMM)
Special Protocol Assessment (SPA)
Stable disease (SD)
Stage I disease
Stage II disease
Stage III disease
Standard-dose chemotherapy
Standard of care
Standard risk disease
Standard therapy
Stem cell
Stem cell transplant
Stevens-Johnson syndrome
Stomatitis
Stringent complete response
Stromal cell
Supplemental New Drug Application (sNDA)
Supportive care
Synergistic
Syngeneic stem cell transplant
T cell
T lymphocyte
Tandem transplant
Teratogenic
Thalomid (thalidomide)
Thrombocytopenia
Time to progression (TTP)
Tissue-type plasminogen activator (t-PA)
Toxic epidermal necrosis (TEN)
Translocation
Treatment cycles
Tumor-induced hypercalcemia (TIH)
Tumor lysis syndrome
Tumor microenvironment
Tumor necrosis factor-alpha (TNF-a)
Urinalysis
Urine electrophoresis (UEP)
VAD
Vascular endothelial growth factor (VEGF)
Velcade® (also known as bortezomib)
Vertebroplasty
Very good partial response (VGPR)
Vincristine
White blood cell (WBC)
Zofran® (ondansetron)

383 Main Avenue, 7th Floor Norwalk, CT 06851
Phone 1-203-229-0464

Donate

Accessibility Terms of Use Privacy Policy Donor Privacy Policy EEA Privacy Policy EEA Cookie Policy Our Sponsors Careers Contact Us

The MMRF is a registered 501(c)(3) non-profit. Tax ID: 06-1504413. For donations please mail to: P.O. Box 414238 Boston, MA 02241-4238

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties.Ok Privacy policy